In the industry's words – Germany's BVMed
This article was originally published in Clinica
Germany is the third-biggest medical technology market in the world, valued at €25bn per annum, and by far the largest in Europe. While the industry continues to grow despite the difficult economic climate, it faces other hurdles. Dr Meinrad Lugan, chairman of German medtech industry BVMed, discusses what these challenges are and how its members – made up of around 230 medtech manufacturers and service providers – are tackling these issues
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.